NCATS Therapeutics Discovery Program expects to commit up to $20 million in FY2013 to fund six to eight awards. X02 pre-applications due August 14, 2012

Discovering New Therapeutic Uses for Existing Molecules is a collaborativepilot programdesigned to develop partnerships between pharmaceutical companies and the biomedical research community to advance therapeutic development. This innovative program matches researchers with a selection ofmolecular compounds from industryto test ideas for new therapeutic uses, with the ultimate goal of identifying promising new treatments for patients.

The National Center for Advancing Translational Sciences (NCATS) seeks to develop a therapeutics discovery pilot program to explore new therapeutic uses for proprietary drug candidates (Agents) across a broad range of human diseases. This innovative program will match Agents and associated data from pharmaceutical company partners with the best ideas for new therapeutic uses from the biomedical research community.

This FOA , PAR-12-203, encourages X02 pre-applications (Due August 14, 2012 , by 5:00 PM local time of applicant organization) for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules. The X02 pre-application is the first step in the application process for RFA-TR-12-004 and RFA-TR-12-005; applicants must read both of the companion FOAs. The X02 pre-applications will be evaluated by a panel of outside experts for scientific and technical merit.

Investigators whose X02 pre-applications are judged to be the most meritorious will be notified of the opportunity to submit a UH2/UH3 or UH3 application under the Limited Competition for RFA-TR-12-004 or RFA-TR-12-005. No awards will be made under the PAR-12-203 FOA.

Technical Assistance Webinar for Applicants

A technical assistance teleconference will be held on June 25, 2012 from 1:00 to 2:30 PM EST. All prospective applicants are invited to participate. In order to support the number of participants on the conference call, participants are encouraged to register by June 22 via e-mail at Therapeutics.Discovery@nih.gov. Please submit questions to be addressed at this webinar on or before June 22. Answers to the questions will be available on the NCATS Webinar page after the call.

———–

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services